Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

Ultra-thin layers of silk deposited on graphene in perfect alignment represent a key advance for the control needed in microelectronics and advanced neural network development.

Growth stocks are expected to see a further rise as the Federal Reserve prepares to cut rates, with the consensus now being 50 basis points.

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...

The world's largest music company laid out a vision to drive revenue growth through 2028. The FTC report said the companies responsible for controlling spending on drugs were sometimes steering ...

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...

In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

Wells Fargo has recently initiated Exact Sciences Corp (EXAS) stock to Overweight rating, as announced on August 28, 2024, according to Finviz. Earlier, on June 27, 2024, Scotiabank had initiated the ...